Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer

International Journal of Clinical Oncology

Volumn 13, Issue 1, 2008, Pages 66-70

  Rizell, Magnus ^a   Andersson, Mats ^a   Cahlin, Christian ^a   Hafström, Larsolof ^a   Olausson, Michael ^a   Lindnér, Per ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cholangiocellular cancer; Hepatocellular cancer; Primary liver cancer; Sirolimus mTOR inhibitor

Indexed keywords

ALPHA FETOPROTEIN; COTRIMOXAZOLE; GANCICLOVIR; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RAPAMYCIN; VALGANCICLOVIR;

ACNE; ADULT; ADVANCED CANCER; AGED; ARTICLE; BILE DUCT CARCINOMA; BLEEDING; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CYTOMEGALOVIRUS INFECTION; DISEASE MARKER; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; ESOPHAGUS VARICES; FEMALE; GRAFT RECIPIENT; HUMAN; LEUKOPENIA; LIVER CELL CARCINOMA; MALE; MUCOSA INFLAMMATION; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECTUM VARIX; SURVIVAL TIME; TINEA PEDIS; TREATMENT DURATION; TREATMENT RESPONSE; VARICOSIS;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CARCINOMA, HEPATOCELLULAR; CHOLANGIOCARCINOMA; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROTEIN KINASES; SIROLIMUS;

EID: 40149098824     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-007-0733-3     Document Type: Article

References (23)

1. Llovet JM, Bruix J (2004) Unresectable hepatocellular carcinoma: meta-analysis of arterial embolization (letter). Radiology 230: 300-302
2. Neuhaus P, Klupp J, Langrehr J (2001) mTOR inhibitors: an overview. Liver Transpl 7:473-484
3. Ogawa T, Tokuda M, Tomizawa K, et al. (1998) Osteoblastic differentiation is enhanced by rapamycin in rat osteoblast-like osteo-sarcoma (ROS 17/2.8) cells. Biochem Biophys Res Commun 249:226-230
4. Hosoi H, Dilling MB, Shikata T, et al. (1999) Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. Cancer Res 59:886-894
5. Schumacher G, Oidtmann M, Rosewicz S, et al. (2002) Sirolimus inhibits growth of human hepatoma cells in contrast to tacrolimus, which promotes cell growth. Transplant Proc 34:1392-1393
6. Schumacher G, Oidtmann M, Rueggeberg A. (2005) Sirolimus inhibits growth of human hepatoma cells alone or combined with tacrolimus, while tacrolimus promotes cell growth. World J Gastroenterol 11:1420-1425
7. Kim DH, Sarbassov DD, Ali SM, et al. (2002) mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110:163-175
8. Guba M, von Breitenbuch P, Steinbauer M, et al. (2002) Rapamycin inhibits primary and metastatic tumour growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 8:128-135
9. Rizell M, Lindner P (2005) Inhibition of mTOR suppresses experimental liver tumours. Anticancer Res 25:789-793
10. Roskamps T (2006) Liver stem cells and their implication in hepatocellular and cholangiocarcinoma. Oncogene 25:3818-3822
11. Guba M, Koehl GE, Neppl E, et al. (2005) Dosing of rapamycin is critical to achieve an optimal antiangiogenic effect against cancer. Transpl Int 18:89-94
12. Franz DN, Leonard J, Tudor C, et al. (2006) Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol 59:490-498
13. Therasse P, Arbuck SG, Eisenhauer EA, et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216
14. Therasse P, Eisenhauer EA, Verweij J. (2006) RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer 42:1031-1039
15. Ratain MJ, Eckhardt G. (2004) Phase II studies of modern drugs directed against new targets: If you are fazed, too, then resist RECIST. J Clin Oncol 22:4442-4445
16. National Cancer Institute. Common terminology criteria for adverse events (CTCAE). Version 3.0 Published date June 10, 2003, Ncl, Rockville
17. Rizell M, Cahlin C, Friman S, et al.(2005) Impressive regression of primary liver cancer after treatment with sirolimus. Acta Oncol 44:496
18. Xu X, Kobayashi S, Qiao W, et al.(2006) Induction of intrahepatic cholangiocellular carcinom by liver-specific disruption of Smad4 and Pten in mice. J Clin Invest 116:1843-1852
19. Sahin F, Kannangai R, Adegbola O, et al. (2004) mTor and p70 s6 kinase expression in primary liver neoplasms. Clin Cancer Res 10:8421-8425
20. Torimura T, Sata M, Ueno T, et al. (1998) Increased expression of vascular endothelial growth factor is associated with tumour progression in hepatocellular carcinoma. Hum Pathol 29:986-991
21. Wang T E, Kao C R, Chen L T, et al. (2004) Salvage therapy for hepatocellular carcinoma with thalidomide. World J Gastroenterol 10:649-653
22. Schwartz J D, Schwartz M, Goldman D, et al. (2005) Bevacizumab in hepatocellular carcinoma (HCC) in patients without metastasis and without invasion of the portal vein. J Clin Oncol 2005 ASCO Annual Meeting Proceedings 23:412
23. Kneteman NM, Oberholzer J, Al Saghier M, et al. (2004) Sirolimusbased immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transpl 10:1301-1311